Special Issue "Vaccine Adjuvants"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (15 December 2013)
Dr. Edward Lavelle
Adjuvant Research Group, School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland
Interests: adjuvant; vaccine; mucosal; inflammasome; particulate adjuvant; innate immunity; nanoparticle
The field of vaccine adjuvant research is very dynamic and is expanding across both academic and industrial sectors. In tandem with the increased scope of vaccination beyond traditional prophylactic approaches, novel therapeutic vaccine strategies for chronic infection diseases, cancer and other indications demand the identification of new and improved targeted adjuvant strategies. Vaccine adjuvants can serve a range of functions including amplifying, directing and regulating immune responses but also protecting antigens, achieving multimeric antigen presentation and controlling antigen release. This issue will address the potential of novel adjuvant strategies to modulate innate and adaptive immune responses in order to facilitate the development of improved prophylactic or therapeutic vaccines. There is a specific focus on particulate vaccine adjuvants, however, contributions on other established and experimental adjuvants or their modes of action are welcome.
Dr. Edward Lavelle
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- particulate adjuvant
- innate immunity
Article: HSP70 Promoter-Driven Activation of Gene Expression for Immunotherapy Using Gold Nanorods and Near Infrared Light
Vaccines 2014, 2(2), 216-227; doi:10.3390/vaccines2020216
Received: 5 December 2013; in revised form: 25 February 2014 / Accepted: 10 March 2014 / Published: 25 March 2014| PDF Full-text (839 KB) | HTML Full-text | XML Full-text
Article: Vaccine Adjuvants in Fish Vaccines Make a Difference: Comparing Three Adjuvants (Montanide ISA763A Oil, CpG/Poly I:C Combo and VHSV Glycoprotein) Alone or in Combination Formulated with an Inactivated Whole Salmonid Alphavirus Antigen
Vaccines 2014, 2(2), 228-251; doi:10.3390/vaccines2020228
Received: 16 December 2013; in revised form: 21 February 2014 / Accepted: 13 March 2014 / Published: 25 March 2014| PDF Full-text (574 KB) | HTML Full-text | XML Full-text
Review: Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators
Vaccines 2014, 2(2), 252-296; doi:10.3390/vaccines2020252
Received: 27 December 2013; in revised form: 20 March 2014 / Accepted: 28 March 2014 / Published: 10 April 2014| PDF Full-text (530 KB) | HTML Full-text | XML Full-text
Vaccines 2014, 2(2), 297-322; doi:10.3390/vaccines2020297
Received: 3 January 2014; in revised form: 22 March 2014 / Accepted: 28 March 2014 / Published: 14 April 2014| PDF Full-text (694 KB) | HTML Full-text | XML Full-text
Vaccines 2014, 2(2), 323-353; doi:10.3390/vaccines2020323
Received: 11 February 2014; in revised form: 27 March 2014 / Accepted: 28 March 2014 / Published: 25 April 2014| PDF Full-text (887 KB) | HTML Full-text | XML Full-text
Article: Caspase-1 Dependent IL-1β Secretion and Antigen-Specific T-Cell Activation by the Novel Adjuvant, PCEP
Vaccines 2014, 2(3), 500-514; doi:10.3390/vaccines2030500
Received: 17 February 2014; in revised form: 2 June 2014 / Accepted: 4 June 2014 / Published: 26 June 2014| PDF Full-text (1029 KB) | HTML Full-text | XML Full-text
Last update: 30 April 2013